Q2 2024 Trevi Therapeutics Inc Earnings Call Transcript
Key Points
- Trevi Therapeutics Inc (TRVI) is making significant progress in its clinical trials for chronic cough and idiopathic pulmonary fibrosis (IPF), with several data readouts expected by year-end.
- The company has bolstered its team by hiring Dr. Meg Garin, who has experience in progressing clinical development, to oversee the RIVER trial.
- The Phase 2a RIVER trial in refractory chronic cough (RCC) is progressing well, with approximately 80% of subjects enrolled and data expected in the fourth quarter of this year.
- Trevi Therapeutics Inc (TRVI) has a strong cash position with $69.5 million in cash, cash equivalents, and marketable securities, providing a runway into 2026.
- The company is conducting supportive studies, including a human abuse potential study and a respiratory physiology study, to inform the development path forward for Haduvio in chronic cough conditions.
- Trevi Therapeutics Inc (TRVI) reported a net loss of $12.4 million for the second quarter of 2024, an increase from a net loss of $7.1 million in the same quarter of 2023.
- Research and development expenses increased significantly to $10 million during the second quarter of 2024, compared to $5.8 million in the same quarter of 2023.
- There is an imbalance in the enrollment of subjects between the two stratification arms in the RIVER trial, which may require keeping the study open longer to balance the arms.
- The company faces challenges in maintaining premium pricing for Haduvio in RCC while optimizing its value without cannibalizing the IPF market.
- The potential for regulatory challenges exists, particularly concerning the human abuse potential study and the scheduling of nalbuphine ER.
Good afternoon. And welcome to the Trevi Therapeutics second-quarter 2024 earnings conference call. (Operator Instructions) Please note this event is being recorded.
Various remarks that management makes during this conference call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor act, Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factor section of the company's most recent quarterly report on Form 10-Q, which the company filed with the SEC this afternoon. In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as representing the company's views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
